Daar E, DeJesus E, Ruane P, et al. Phase 3 randomized, controlled trial of switching to fixed-dose bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from boosted protease inhibitor-based regimens in virologically suppressed adults: week 48 results. Program and abstracts of the 2017 IDWeek annual meeting; October 4-8, 2017; San Diego, California. Abstract LB-4.